Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-(2-nitro-4-(trifluoromethyl)benzoyl)cyclohexane-1,3-dione
2. 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
3. Ntbc Cpd
4. Orfadin
1. 104206-65-7
2. Orfadin
3. 2-(2-nitro-4-(trifluoromethyl)benzoyl)cyclohexane-1,3-dione
4. Nitisone
5. Ntbc
6. 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione
7. 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione
8. 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione
9. Sc 0735
10. Sc-0735
11. 2-(alpha,alpha,alpha-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione
12. 1,3-cyclohexanedione, 2-[2-nitro-4-(trifluoromethyl)benzoyl]-
13. 2-{[2-nitro-4-(trifluoromethyl)phenyl]carbonyl}cyclohexane-1,3-dione
14. Chembl1337
15. Chebi:50378
16. 1,3-cyclohexanedione, 2-(2-nitro-4-(trifluoromethyl)benzoyl)-
17. Mfcd01752192
18. Sc0735
19. K5bn214699
20. Nitisinone [inn]
21. Nitisinone [usan:inn]
22. Nitisinona
23. Nitisinonum
24. Smr002529592
25. Orfadin (tn)
26. Nitisinone (jan/usan/inn)
27. Unii-k5bn214699
28. Nityr
29. Fe-0200
30. 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione
31. Nitisinone [mi]
32. Nitisinone [jan]
33. Nitisinone [usan]
34. Nitisinone [vandf]
35. Nitisinone [mart.]
36. Nitisinone [who-dd]
37. Bidd:pxr0129
38. Mls004774025
39. Mls006011955
40. Nitisinone [ema Epar]
41. Schembl338795
42. Ambz0071
43. Gtpl6834
44. Dtxsid9042673
45. Nitisinone [orange Book]
46. Nitisinone, >=95% (hplc)
47. Schembl15996621
48. Hms3740a15
49. Hms3870k03
50. Bcp15276
51. Hy-b0607
52. Bdbm50088804
53. Nsc773149
54. Rb3134
55. S5325
56. Akos015891363
57. Akos015994590
58. Zinc100014475
59. Am62666
60. Ccg-222085
61. Db00348
62. Ex-6233
63. Nsc-773149
64. Sb19017
65. Ncgc00185778-01
66. Ncgc00185778-02
67. Ncgc00185778-04
68. Ncgc00185778-07
69. Ac-26934
70. Sy047291
71. Db-014936
72. Ft-0672739
73. D05177
74. A800922
75. Sr-01000940576
76. J-505680
77. Q3877355
78. Sr-01000940576-2
79. Ntbc; Nitisone; Sc0735; Sc 0735; Sc-0735
80. Z1514110653
81. 1,3-cyclohexanedione,2-[2-nitro-4-(trifluoromethyl)benzoyl]-
82. 2-(2-nitro-4-(trifluoromethyl)-benzoyl)cyclohexane-1,3-dione
83. 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione;nitisinone
84. 2-(.alpha.,.alpha.,.alpha.-trifluoro-2-nitro-p-tuluoyl)-1,3-cyclohexanedione
Molecular Weight | 329.23 g/mol |
---|---|
Molecular Formula | C14H10F3NO5 |
XLogP3 | 2.3 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 2 |
Exact Mass | 329.05110691 g/mol |
Monoisotopic Mass | 329.05110691 g/mol |
Topological Polar Surface Area | 97 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 524 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Orfadin |
PubMed Health | Nitisinone (By mouth) |
Drug Classes | Gastrointestinal Agent |
Drug Label | Orfadin contains nitisinone, which is a hydroxyphenyl-pyruvate dioxygenase inhibitor indicated as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1 (HT-1). Nitisinone occurs as white to... |
Active Ingredient | Nitisinone |
Dosage Form | Capsule |
Route | Oral |
Strength | 5mg; 2mg; 10mg |
Market Status | Prescription |
Company | Swedish Orphan |
2 of 2 | |
---|---|
Drug Name | Orfadin |
PubMed Health | Nitisinone (By mouth) |
Drug Classes | Gastrointestinal Agent |
Drug Label | Orfadin contains nitisinone, which is a hydroxyphenyl-pyruvate dioxygenase inhibitor indicated as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1 (HT-1). Nitisinone occurs as white to... |
Active Ingredient | Nitisinone |
Dosage Form | Capsule |
Route | Oral |
Strength | 5mg; 2mg; 10mg |
Market Status | Prescription |
Company | Swedish Orphan |
Used as an adjunct to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1.
FDA Label
Hereditary tyrosinemia type 1 (HT 1)
Orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.
Alkaptonuria (AKU)
Orfadin is indicated for the treatment of adult patients with alkaptonuria (AKU).
Treatment of adult and paediatric patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
Treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.
Treatment of tyrosinemia type 1
Hereditary tyrosinemia type 1 occurs due to a deficiency in fumarylacetoacetase (FAH), the final enzyme in the tyrosine catabolic pathway. Nitisinone inhibits catabolism of tyrosine by preventing the catabolic intermediates. In patients with HT-1, these catabolic intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate, which are responsible for the observed liver and kidney toxicity. Succinylacetone can also inhibit the porphyrin synthesis pathway leading to the accumulation of 5-aminolevulinate, a neurotoxin responsible for the porphyric crises characteristic of HT-1.
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
A16AX04
A16AX04
A16AX04
A - Alimentary tract and metabolism
A16 - Other alimentary tract and metabolism products
A16A - Other alimentary tract and metabolism products
A16AX - Various alimentary tract and metabolism products
A16AX04 - Nitisinone
Absorption
The capsule and liquid formulations are bioequivalent in both the plasma concentration-time curve and maximum plasma concentration (Cmax).
~54 hours
Nitisinone is a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme upstream of fumarylacetoacetate hydrolyase (FAH) in the tyrosine catabolic pathway. By inhibiting the normal catabolism of tyrosine in patients with hereditary tyrosinemia type 1 (HT-1), nitisinone prevents the accumulation of the catabolic intermediates maleylacetoacetate and fumarylacetoacetate.
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-08-28
Pay. Date : 2020-08-06
DMF Number : 33948
Submission : 2019-07-17
Status : Active
Type : II
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-02-01
Pay. Date : 2016-12-26
DMF Number : 31250
Submission : 2017-01-02
Status : Active
Type : II
Date of Issue : 2024-02-20
Valid Till : 2026-12-06
Written Confirmation Number : WC-0416
Address of the Firm :
NDC Package Code : 58159-037
Start Marketing Date : 2020-02-05
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-12-22
Pay. Date : 2016-10-11
DMF Number : 30680
Submission : 2016-10-19
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35810
Submission : 2021-03-31
Status : Active
Type : II
Date of Issue : 2021-09-17
Valid Till : 2022-08-13
Written Confirmation Number : WC-0171Amendment
Address of the Firm :
NDC Package Code : 43235-0016
Start Marketing Date : 2020-03-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-09-21
Pay. Date : 2021-08-02
DMF Number : 36026
Submission : 2021-07-31
Status : Active
Type : II
Date of Issue : 2020-07-23
Valid Till : 2023-05-11
Written Confirmation Number : WC-0273
Address of the Firm :
NDC Package Code : 76055-0043
Start Marketing Date : 2019-07-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Complete
Rev. Date : 2020-08-28
Pay. Date : 2020-08-06
DMF Number : 33948
Submission : 2019-07-17
Status : Active
Type : II
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Complete
Rev. Date : 2017-02-01
Pay. Date : 2016-12-26
DMF Number : 31250
Submission : 2017-01-02
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-09-21
Pay. Date : 2021-08-02
DMF Number : 36026
Submission : 2021-07-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35810
Submission : 2021-03-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-12-22
Pay. Date : 2016-10-11
DMF Number : 30680
Submission : 2016-10-19
Status : Active
Type : II
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
Date of Issue : 2024-02-20
Valid Till : 2026-12-06
Written Confirmation Number : WC-0416
Address of the Firm : Plot No. 111 SIDCO Industrial Estate, Kakkalur Thiruvallur-602003 Tamil Nadu, In...
Date of Issue : 2021-09-17
Valid Till : 2022-08-13
Written Confirmation Number : WC-0171Amendment
Address of the Firm : (Unit-III), Village-Bhagwanpur, Barwala Road, Derabassi, Dist-Mohali (Punjab)
Date of Issue : 2020-07-23
Valid Till : 2023-05-11
Written Confirmation Number : WC-0273
Address of the Firm : Plot No. 34A, J.N.Pharma City, Thanam (V), Parawada (M), Vishakhapatnam-District...
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
NDC Package Code : 55463-0034
Start Marketing Date : 2004-08-17
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
NDC Package Code : 58159-037
Start Marketing Date : 2020-02-05
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (35kg/35kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 66005-0046
Start Marketing Date : 2015-09-10
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 76438-004
Start Marketing Date : 2019-06-18
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 43235-0016
Start Marketing Date : 2020-03-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 76055-0043
Start Marketing Date : 2019-07-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 68022-7058
Start Marketing Date : 2018-12-26
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
About the Company : Established in 2012, Nuray Chemicals Pvt Ltd is an API manufacturer for highly regulated markets. Its manufacturing facility with state-of-the-art R&D is located near Chennai in th...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...
About the Company : Alven strengths lie in the development of highly complex molecules, technological leadership and efficiency in production. All our R&D work is driven by basic rule – the result o...
About the Company : Danesh Kimia Pharmed Co. was established on 2011 by industrial and university researchers in order to invest on the production of new pharmaceutical molecules and their ready to us...
About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...
About the Company : Established in the early 90’s SCL offers a wide range of Active Pharmaceutical Ingredients and Intermediates to its customers worldwide. SCL’s products are exported to Europe, ...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 2MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : RX
Registration Country : USA
Brand Name : NITISINONE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 5MG
Packaging :
Approval Date : 2023-05-25
Application Number : 216201
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : NITISINONE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 5MG
Packaging :
Approval Date : 2022-05-26
Application Number : 212390
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : Sweden
Brand Name : Orfadin
Dosage Form : ORAL SUSPENSION
Dosage Strength : 4 MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Orfadin
Dosage Form : Nitisinone 10Mg 60 Units Oral Use
Dosage Strength : 60 cps 10 mg vial
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Orfadin
Dosage Form : Capsule, hard
Dosage Strength : 5 mg
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Brand Name : ORFADIN
Dosage Form : Hard Capsule For Oral Use
Dosage Strength : 5 mg
Packaging : 60 UNITS 5 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info : DISCN
Registration Country : USA
Brand Name : NITISINONE
Dosage Form : CAPSULE;ORAL
Dosage Strength : 2MG
Packaging :
Approval Date : 2023-01-09
Application Number : 215908
Regulatory Info : DISCN
Registration Country : USA
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?